A Double-Blind, Randomized, Placebo-Controlled, Cross-Over Phase IIa Trial to Evaluate the Efficacy of CVXL-0107 on Parkinson-Related Symptoms and Levodopa-Induced Dyskinesia in Advanced Parkinson’s Disease
Objective: To evaluate the efficacy of CVXL-0107 on motor symptoms and on levodopa-induced dyskinesia in advanced Parkinson’s disease (PD) patients. Background: CVXL-0107 is a glutamate…The Akt/mTOR/P70S6K/4EB-P1 signaling pathway is activated by metformin in a toxin-induced cellular model of Parkinson’s disease
Objective: To investigate the effects of metformin on the Akt/mTOR/P70S6K/4EB-P1 signaling pathway in a cellular model of Parkinson’s disease (PD). Background: Metformin is a drug…Five year longitudinal change in the MDS-UPDRS scores in early Parkinson’s disease participants: Results from the PPMI Study
Objective: To determine the longitudinal change in the Movement Disorder Society –Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) in Parkinson’s disease (PD) participants who were untreated…Randomized Parkinson’s Trial of GDNF Administered via Intermittent Intraputamenal Convection-Enhanced Delivery.
Objective: Assesing the neurorestorative effect of GDNF. Background: GDNF is a potent neurotrophic factor. A previous placebo-controlled trial, however, at 6 months, failed to demonstrate…Disease-modification in Translational Models of Parkinson’s disease by the Rho Kinase Inhibitor Fasudil
Objective: To evaluate the therapeutic potential of the Rho Kinase (ROCK) inhibitor Fasudil in translational models of Parkinson’s disease (PD). Background: There is still a…Intracerebroventricular administration of dopamine: A new therapeutic concept for Parkinson’s disease?
Objective: In this study, we aim to demonstrate that continuous i.c.v. infusion of dopamine close to the striatum is a feasible and highly efficient treatment…AAV-mediated over-expression of VEGF-B in PINK1 gene knockout rats increases striatal dopamine content
Objective: To evaluate overexpression of the neuroprotective vascular endothelial growth factor B (VEGF-B) in a genetic Parkinson’s disease (PD) model. Background: We have shown in…Identification of a trehalose treatment regimen with potential to be translated into a therapeutic for the treatment of Parkinson’s disease
Objective: To evaluate the preclinical efficacy of trehalose and to identify a dosing regimen that can be used to clinically evaluate trehalose as a disease-modifying therapy…NS-PARK/FCRIN network, the French Clinical Research Network for Parkinson’s disease and Movement Disorders
Objective: The objective of NS-PARK/FCRIN network (http://www.parkinson.network/) is to facilitate and stimulate clinical academic and industrial research in France in the field of Parkinson's disease…Improving Racial and Ethnic Diversity in Parkinson`s Disease Clinical Trials
Objective: To identify and overcome challenges to recruiting minorities in Parkinson's Disease experimental therapeutic trials. Background: Inadequate representation of ethnic and minority population poses substantial…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.